This time I found you an interesting crowdfunding company, HOOLDERS, allows individuals to save simple, cost-effective and accountable manner co-investissant (shareholder) with it from € 500 in qualified and secure companies.

Of companies selected by experts, in the three sectors of innovation technology: health, connected objects and the silver economy. With an assumed selection, HOOLDERS detects the most qualified innovative companies.

The platform has co-financed for near 3 m€ in 15mois. It is the 1st platform of participatory capital funding investing € 500 in the best French companies, alongside venture capital professionals (Fund, Business Angels, Family Office, Venture Capitalist,…).

HOOLDERS is present in France and Belgium. Investors of its platform are to this day France, Belgium and Asia (Hong Kong)(mars 2016)

Sommaire

0.1 What is Hoolders? The description of the company.
0.2 HOOLDERS is the 1st platform of CO-FUNDING in France.

1 Investors
2 Entrepreneurs
- 2.1 Why trust hoolders?
- 2.2 Frequently asked questions
3 Other information
- 3.1 Sponsorship
- 3.2 Who is hoolders?
4 My opinion after the test
5 Conclusion and my opinion
- - 5.0.1 Partager :

What is Hoolders? The description of the company.

HOOLDERS is the 1st platform of CO-FUNDING in France.

It allows individuals to save a simple, cost-effective and responsible manner in co-investissant with it from € 500 in qualified and secure companies.

Co-investment hoolders means that generally HOOLDERS (team or members of the HOOLDERS Club) returned to the Board of Directors of the companies co-fundees, in order to defend the interests of the members of the community.

Of companies selected by experts, in the three sectors of innovation technology: health, connected objects and the silver economy.

With an assumed selection, HOOLDERS detects the most qualified innovative companies.

Because the France growth through innovation, participatory financing platform enables investors to invest from € 500 and support companies in the three sectors which according to Gartner, should the most benefit from technological innovations:

the silver economy
health
objects connected/robotic/big datas.

According to a study by INSEE in 2014, the French rely on average 2,000 euros per year in the lottery, and lose 400 euros. A sum which continues to grow and that pushes us to consider an alternative.

At the same time, the French economy is stagnating, with soft growth, a debt that continues to grow, and a number of unemployed at its highest historical level. Restart our economy involves having companies that innovate and therefore, following the recommendations of the firm Gartner, inve[…]st "in three areas of innovation: health, objects connected – big datas, the silver economy. '' […] ». Unfortunately, access to investment in these innovative companies is still too limited.

The French hold over 11,000 billion euros of savings. This is because it would have to accompany them to secure their funds by investing in our future and our jobs that HOOLDERS has launched the 1st CO-FUNDING platform.

This concept seems to seduce because more than 2 million was invested in 13 months.

Investors

Why invest in hoolders?

To grow its savings and earn money

You have the possibility of added value and / or to receive dividends. The ambition of the co-funding platform is to meet the household savings and the economy of the french, to fructify this savings to the service of the French economy.

Because the principle is really different

Generally HOOLDERS (team or members of the HOOLDERS Club) returned to the Board of Directors of the companies co-fundees, in order to defend the interests of the members of the community.

Because the interests of hoolders are yours

If hoolders enters a company, you can be certain will defend it well.

To diversify your savings

Because there's not that banks in life, you can also invest in projects that you really like.

Because you decide

Completed time or your banker, er sorry your favorite commercial decide for you, resume in hand your savings.

Because the ticket is affordable

You can invest in hoolders from € 500

To diversify

You can invest in many project and have a really custom portfolio and which looks like you

To have a tax deduction

Tax exemption IR
Tax exemption ISF 2016
Tax exemption PEA SMEs

Hoolders, frequently asked questions

Who can invest?

Invest on the HOOLDERS platform is open to all. It is not necessary to be an experienced investor to have access to our investment offers, it is the principle of co-funding.

Individuals: investing, to be major, completing a profile, and the online questionnaire and have provided us proof of identity and proof of address.
Corporations: corporations must provide a Kbis extract in addition to the documents cited previously.

to be exact in the TOU:

Registration on the platform is open to persons of 18 years of age residing fiscally in France and holder of a bank account opened in a credit institution books.
The following information will be requested from the investor wishing to register on the platform and open an investment account:

Name;
First name;
Email;
Mobile number;
Postal address with the country of residence;
Country of birth;
Work;
Employer; and
Indication whether a person is politically exposed or not (PEPs).

The following documents may be required depending on the amount of investments made by the investor:

Proof of address dating from less than 3 months;
Bank proof; and
One or more proofs of identity (national identity, residence permit or passport card).

ICCI and the payment Service Provider reserves the right to refuse or suspend any registration on the platform including when the information provided prove to be false or inaccurate, notwithstanding the declarations made by the investors in the present General Conditions of sale, or when the funds credited to the investment account by the investor is caused an illegal activity or when the operation of investment carried out by the investor contrary to norms French tax or international.
Once the present General Conditions of sale accepted, the registration becomes effective.

Warning: Prior to any investment, you must ensure that you have a full understanding of benefits and risks of the investment and your decision is taken independently, that the operation is appropriate to your situation into account your goals, your experience, your operational and financial resources and other relevant circumstances.

(*) Risk factors

What are the costs?

nothing for the opening of the account

However it y of costs, once for investment, or 5% and once on any more value, variables. see TOU

Commission initial
An initial Commission is due and paid by the investor when one makes an offer of investment.
The amount of the initial Commission is 5% of the amount of the investment proposed by the investor, duty-free.
The amount of the Initial Commission is collected in the investment account only once since the offer of investment of the investor has been issued.

The initial Commission is repaid to the investor when the offer of the investor is not retained at the end of the investment period.
The amount of the initial Commission is communicated to the investor during the finalization of its investment on the platform.
(b) Commissions
When an operation is performed with an intermediate vehicle created by Hoolders, a commission on realized capital gains will be seen by Hoolders. The amount of this commission will be specified at the time of the completion of the investment.

Hoolders fees

Except tariff advantages offered by Hoolders, investment in online companies is accompanied by a 5% HT as the fees regulation. For example, for 1,000 EUR you pay 1,000 euros to the chosen company's capital and 50 euros in fees to Hoolders.

These fees of 5% HT come pay for the services performed, including a non-exhaustive list below:

Standardization of investments documents:
- Financial: Investpaper, appendices financial, Business Plan
- Legal: Negotiation of the Covenant partner and the LOI (letter of intent)
- Legal:
  - Creating/signing of subscription newsletters, law and shareholders ' agreement
  - Drafting and storage for 10 years from the ISF certification / IR
Negotiation of the company valuation
Creation of a holding company, moderator
Free invitation to the Live CrowdFunding (investor meetings – contractors)
In relation with the community via the Hoolders Club investors

The part in red is no longer valid to 26/03/2016 Finally, when an operation is performed with an intermediate vehicle created by Hoolders, a commission of 10% on realized capital gains will be seen by Hoolders. Indeed, the costs of Holding (if its lifetime is less than 5 years), are borne by Hoolders.

The costs are now variable

Note: If you are part of the club hoolders, (*) as a member of the club, the investment costs are offered up to 20,000 euros invested per calendar year.

How to invest?

Depending on your preferences, you:

Go to investment files
Book an investment amount, during the review of the file. Hoolders will take into account your reservation and will contact you to finalize the investment.
Invest safely using the "OK" field. Hoolders teams will contact you to finalize this investment.
Interact with other investors within the HOOLDERS Club

To finalize your investment, you electronically sign related documents (bulletin of subscription, termsheet, shareholders ' agreement, letter of intent) and will transfer to the dedicated account. The documents will be saved and secure in an electronic safe within the CDC Arkinheo (subsidiary of the Caisse des dépôts).

Finally, HOOLDERS you will provide in your account tax (ISF certification, IR) necessary to your statements and legal evidence.

How much invest and what benefits?

In general, the minimum investment is €500.

It is strongly recommended to invest only money that you do not need (cf: how to invest malin). Diversify your portfolio by focusing on the sectors of technological innovations: health, connected objects, silver economy. For example if you have € 10,000 to invest, we recommend that you invest € 1,000 in 10 companies.

By investing in innovative companies enjoy significant tax reductions:

Up to € 45,000 in the wealth tax
Up to £ 9,000 in the context of the income tax
Enjoy tax benefits through the PEA – SMEs

RIGHT OF WITHDRAWAL (BLOGS L.343‐1 AND FOLLOWING OF THE CODE OF MONETARY AND FINANCIAL)

The investor enjoys a right of withdrawal. Contract concluded remotely the investor is advised of the possibility of retracting its commitment. The acceptance of the present General Conditions of sale also causes the agreement of the investor to begin execution of the services offered on the platform before the end of the fourteen day period.
The right of withdrawal may be exercised without any reason, within fourteen (14) calendar days of age following the conclusion of the contract by sending a registered letter with acknowledgement of receipt at ICCI. The investor is reimbursed for the amounts credited on the investment account, excluding the amounts used for operations already carried out.
Therefore, the investor remains obliged to release the amount of the investment securities during the period of withdrawal, even in the event of withdrawal within the legal deadline.

Funny way to ED, I'm wondering whether it is authorized a similar trick, but at least you are warned (be anyway that I explore this point). Good at the same time should be avoided to retract on this kind of project.

What is the risk?

Risk factors

Hoolders draws its members on the risks of investment in unlisted securities. Referenced companies have mostly not yet reached their threshold of profitability and receive little financial resources.

Liquidity risks

Companies are not quoted titles, their liquidity will be assured in the medium term at the time of looking for buyers or an opportunity to exit (entry of an investment fund, redemption by the founders, entering an industrial actor, LBO or listing on a regulated market).

Risk of capital loss

The investor should be aware of the risk of loss of any or all of the capital invested. This is what is written on the site, so the maximum risk is of losing your money, I assumed that the companies are the SAS or structures limiting losses to the amount invested.

This risk is inherent to the activity of capital risk (i.e. investment in the early stages of growth of the company). Despite the analysis carried out by Hoolders and diligence to the study of the files, Hoolders cannot guarantee a return on investment.

Warning

Hoolders SAS selects for its business customers during boot, early or development wishing to make capital increase operations to accelerate their development.

Capital increases presented on Hoolders.com, can in some cases do not lead. For example, an enterprise not collecting a sufficient amount may trigger the increase of capital, the "threshold of feasibility" of each operation is communicated in the briefing made available to applicants subscribers. Similarly, as part of a proposal by various investors (apart), presented corporations may have to reconsider the principle of a capital increase or the amount of the latter.

Taxation

[ICCI fournit, au titre des opérations sur valeurs mobilières, une déclaration unique annuelle, appelée Imprimé Fiscal Unique (IFU). Il s’agit du formulaire n°2561 à laquelle est annexé, le cas échéant, un état des intérêts de créances de toute nature et produits assimilés, dénommé état « directive ».
L’IFU est communiqué à chaque Investisseur, chaque année.]

Entrepreneurs

Why trust hoolders?

The mission of Hoolders is to meet the household savings and the economy of the french, to fructify this savings to the service of the French economy.

Technological innovation is the cornerstone of our ambition.

Hoolders is designed to help you assemble your project, supporting you in structuring your project and its folder to be the intermediary to raise the first funds for your financial contribution and prepare for external funding of the project.

Your project on Hoolders will allow you besides having access to your first public, to be able to communicate and receive advice or even community experts.

Frequently asked questions

What are the selection criteria?

As investment, we select folders 'premium', with a priority to innovation. Our grid focuses on 4 components:

(1) the sector

The undertaking must be in one of the three sectors of technological innovations according to Gartner:

health
the silver economy
connected objects

Related sectors to them are accepted also. For example welfare: sport, hygiene of life (health related), mobile Application using a mass of data (related to the connected objects, big datas, robotics).

(2) the degree of innovation of the project

The product must be:

innovative and changing the habits of its market
scalable ideally. That is to say highly disruptive

(3) the company, the team

The company must have:

A team qualified, additional
Conducted a proof of concept (non-biotech, medtech). I.e. have already made a beginning of CA (> €0).
Having won awards or competitions would be a plus

(4) the market, the need for financing

An enterprise should:

Being in an open market where tickets are still to take
Search more than € 200,000 funding (according to page of the site)
.

how much can I borrow?

At least € 200,000 (in fact there was inconsistency in the 2 pages, one of 150 200)

How to create my project on Hoolders?

To submit your project to Hoolders, it is very simple, just click here.

I am entrepreneur, how to protect confidential information in my project?

Aware that privacy is essential for the success of your projects, Hoolders will tell you what information that will be posted online or not, so that you retain the decision to disseminate the information you want.

I am a company or an association, I would like to work towards more ethical and solidarity

Hoolders is always open to new synergies with the actors of the company or associations, who wish to advance in the daily social and ethical values.

Where to find further information?

The General conditions of use describe all of the internet services provided by Hoolders, the responsibilities of the various parties, users, contractors…

Ask a Hoolders representative present on the site, or simply send us your question at the following address:plateforme@Hoolders.com

What is your process?

Our Selection process

Make your fundraising in just 5 steps with Hoolders.

Any innovative company client Hoolders must pass these selection steps in order to access the fundraising phase.

(1) screening

Fill in and drop your folder of funding to initiate the screening operation
Customize your fundraising page: this is your communication tool
Study your folder in internal (selection) Committee and voting phase implementation

(2) accession to the community

Improve your reputation by getting a maximum of support and recommendations
Promote your page of fundraising to a wide audience, give all chances to your innovative company for this phase of selection
Get investment intentions in your innovative company

(3) due Diligence pushed

Financial, legal and sectoral study of your innovative company and the need for funding
Implementation of the investor pack (Investpaper, Memorandum…)
Validation by the selection board (or Committee of experts of Hoolders) then launch of the legal calendar of the fundraising operation.

(4) financing

Meet your future investors during the Crowdfunding Live
Turn the expressions of interest in investment in your innovative company
Harvest investments, electronic signature of legal documents and completion of the fundraising operation

(5) post-financing

Harvest investments, electronic signature of legal documents and completion of the fundraising operation
Make your innovative business thrive by taking advantage of the social network of experts and Hoolders Club
Share with your shareholders and easily pass the bond of your innovative company information.

WHERE to place a folder?

DEPOSIT YOUR FINANCE DOCUMENTS

How to succeed its fundraising?

The fundraising to finance startup (seed capital) or the development of a company (capital development). In both cases, investors will take participation in the funded company.

Fundraising is an indispensable to the development of a company. The contractor shall be very attentive and there put a lot of energy to succeed its fundraising. Before embarking on this process, he must have reflected on the consequences inherent in this operation. It is therefore advisable to reflect the questions below and familiarize yourself with the vocabulary used:

Are you ready to embark on the adventure of raising funds?

Have you already made your business plan, your Executive Summary?

How many do you need to be able to successfully complete your project and your goals? Have you thought about the dilution of the shares of the creator?

What stage of development (metric) do you want to achieve through this fundraiser?

If you are not able to respond to these questions, it is likely that you are not ready to embark on a fundraising. Your project could have a lot of potential but you will miss opportunities because you are not adequately prepared.

Have you assessed your knowledge concerning the phase of fundraising?

Am I able to be able to promote my company? Can I defend my interests during the investment agreement? Should I negotiate myself shareholder and handle the closing?

The road up to the receipt of funds is fraught with obstacles and you must be armed for each of them.

The phases of negotiations (due diligence, valuation, investment contract) and closing (letter of intent, drafting of the Pact of shareholders and terms sheets) require a particularly extensive technicality both legal and financial.

If you've already experienced at least once this experience, you will have a definite advantage. Otherwise, it is wise to entrust this work to an expert in financial optimization.

How can I convince investors?

This cannot be improvised, the preparation is necessary and it must be rigorous and careful to try to attract potential investors. In addition investors allocate their funds to a project based on various criteria such as:

The size of the market target
The team (the skills of leaders,…)
The problem solved, especially the scalability of the product and innovation
Financial ratios and consistent projections.

Nevertheless each investor and each investment funds have very specific criteria.

Who should I contact?

The fundraising is often performed with several types of structures. And the best advice to follow is well to surround himself:

Partners who accompany you: there are different actors such as those that help business creation or childcare for companies like incubators.
Investors: select, meet and present your company to several investors can be very time consuming. On the other hand, if you have neither the time, nor the address book or your fundraising skills, it is preferable to call with a Cattlemen's Fund. Otherwise, you can contact networks of business angels, seed funds identified by UniCer (National Union of investors in Capital for regional companies) or the AFIC (French Association of capitalists).

How is fundraising for Hoolders

Innovation is the key of French growth, Hoolders offers savers to accompany and to invest from €500, in companies active in the three most promising sectors: the Silver Economy, health, and the connected objects. According to Gartner, these three areas are the key to innovation by 2020.

Hoolders represents the 1st co-funding platform where leaders of the platform undertake to your side by investing.

The objective of the platform is simply to allow individuals to build their savings of simple, cost-effective and accountable manner, while developing the French economy.

Anxious to accompany the best possible the most promising future enterprises, has Hoolders of a pole of experts whose crucial role is to select the most demanding businesses and the more consistent and attractive projects.

In addition, Hoolders and his associates invest systematically in selected companies, along with professional investors (funds, Family Office, banks, Business Angels…), winning both the interest companies and trust of the general public.

For Hoolders, everyone can become investor and actor of the businesses of tomorrow.

To be eligible for a quality with Hoolders accompaniment, companies must:

be in areas of innovation: namely the Silver Economy, health and the connected Objects
need a £ 200,000 funding
be scalable
completing a proof of concept

Other information

Sponsorship

Nothing for the moment.

Who is hoolders?

HOOLDERS, ICCI brand.

International Consultancy Coverage Investment SAS is a joint stock company simplified to the share capital of EUR 17.756, whose headquarters is located at 130 rue du 8 Mai 1945, Nanterre, France, registered with the registry of Commerce and companies of Nanterre under the number 752 316 877, registered with the Agency for the register of intermediaries in Assurance (ORIAS) under the number 13006195 as a broker in banking and payment services (COBSP), registered with the ANACOFI-CIF as Board in investment financial (CIF).

Mark Hoolders (www.hoolders.com) has been developed on April 28, 2014 as part of its development in CrowdFunding.

Team

the team leader

Harold zime, founding president

Harold has 5 years of experience in finance, trading and market risk, walking in banking groups in Paris and Hong Kong. He occupied shares/hybrid, actions and rate structured derivatives. He presides over Hoolders and brings clearly by his knowledge of financial products. Of the project and having worked upstream on the realization of this business model, it gathers, motivates and organising the different areas contributing to the development of a successful implementation of this undertaking.

Guillaume TOURNIAIRE, responsible for products – co-founder

With a solid experience of 5 years as a structureur of products on interest rates, credit or inflation in France, Belgium and Hong Kong, Guillaume directs the structuring of product offer in Hoolders. His mastery of financial products, of all their parameters, make him someone key in the structure.

Thierry de Catheu, Director Hoolders health – associated

Manager experimented with 30 years of experience in the industry of health in big groups (Johnson & Johnson, Smith + Nephew, Sorin Biomedica, Cochlear), distributors and start-up. Has extensive expertise of the placing on the market, the launch and the development of new therapeutic solutions. Strategic consultant since January 2013 with start-up Medtechs and Biotechs, advise project promoters in their fundraising.

Noam Revah, Director Hoolders real estate – associate

He made his debut in London Investment Bank, first at Barclays and Goldman Sachs. In 2007, he left London for Paris and founded two investment structures: Pandora, real estate investment company (SIIC) recovered 40 M€ and Glaizer, producer of innovation, renamed in 2013 Kerai. In 2014, he founded Black Swann Follow Capital, LBO Fund with 100 M€, whose vocation is to invest in companies valued between 500 K€ and 100 M€.

The intern (ad found in March 2016) 🙂

the strategic Committee

Pierre BANAL former President of ACEC – founder of ABC Private Equity

Didier LEGROS Homme of network – communicating

Christophe GOY leader from Oh Yes! -Former President of CSAA. The Public System

Viviane NEITER President Champagne – Ardennes financial

The selection board

After validation of the financing by the community investors and the team record of Hoolders, a team of professionals has been formed to evaluate the projects that will be submitted to the funding. The jury is composed of independent persons of the company Hoolders. These people have 20 years of experience, they are experts in their field of activity and volunteer work in the jury, they meet every month.

What is the mission of the selection board?

The jury selects projects. It notes the projects relying on an evaluation grid according to criteria such as:

Skills of / the creator (s) of the project
The management team
The potential of the target market
Financial ratios

It is not an exhaustive list of criteria but the jury has an objective eye when in the selection of projects. It is important to avoid financing firms that could pose a major risk for investors.

The Board members brings an opinion once per month to financing projects that their are proposed.

Eric Legale

Managing Director of Issy Media and Director of the digital agency SO Digital | + 20Y experiences | Issy les Moulineaux

Xavier Corman

Co-founder of eDeBex.com. + 20Y years of experiences. Brussels

Pascale Lardin

Founder of NowForever, formerly Director of European Affairs within Altran. + 20Y experiences | Issy les Moulineaux

Bernard Paranque

Delegate-general for the Euroméditerranée, Professor of finance at Kedge Business School, of the «Finance otherwise: investment, solidarity, responsibility ". + 20Y experiences | Marseille

Gilles Pulvermuller

Researcher, Manager of the incubator scientific "La Haute Borne", responsible for recovery in the CNRS| + 20Y experiences | Lille

HOOLDERS health

Thierry of Catheu charge of Health / Life Sciences

Thierry SARDA VP Marketing and branch in Medtechs international

More than 20 years in the Life Sciences and medical devices in the functions of sales, marketing and general management in France and abroad. Strong commitment in the industrial unions of the sector in France and in Europe respectively as President and member of the Board of Directors. Expertise in accessing the market, relations with health authorities, health ecosystem, and the marketing of innovative medical products to hospital and care of city and at home. An active member of Business Angels health.

Olivier Favre-Bulle 3Biotech President

Leader with experience over 20 years in the Life Sciences industries the duties of head of industrialization and Operations preclinical and clinical, and Directorate General in France and abroad. Has extensive expertise in the development of chemical and biological processes, the CMC development and management of international drug development projects.

Why a Pole Health / Life Sciences?

Of academic research globally recognized in the field of the life sciences, many projects emerge each year in France. These start-ups and innovative companies particularly need funds to carry out their development and become Europe of tomorrow's leaders.

The year 2014 has been particularly rich in introduction in scholarship and success stories which have put France on the front of the world stage for the biotechs. Hoolders co-investment and development of participatory financing (equity, credit) meets a real demand and allows to fill the lack of funding in certain critical phases of the development of businesses for the future of this sector.

Investing in this area requires special expertise. Thus, to create the optimal conditions in the selection and support of projects, Hoolders relies on a Committee of health experts / community Hoolders health and Life Sciences / Life Sciences where all profiles and know-how are available to meet the requirements of this domain

Our Mission

Accompany and facilitate fundraising of promising entrepreneurs in innovative projects and enable them to stay focused on their business (product development, Clinical Affairs, regulatory etc.)
Provide a single window: Hoolders is the entry point of a platform for co-financing involving the institutional, the seed fund, Business Angels, capital funds risks, family offices alongside the crowdfunders.
Provide rapid funding, turnkey (administrative, legal,…), because we are aware of the issues.
To allow entrepreneurs, when projects are sufficiently secured to think big and go enough fast especially in their international development.
Ensure the best development of the company and the best possible performance for our subscribers through our selectivity in projects, the quality of the accompaniment in placing at the service of entrepreneurs the expertise, networks and know-how of the Hoolders team and the entire community Hoolders.
Offer our ecosystem's Health / Life Sciences which are represented professions of health, industrial health, health Institutions, professional associations and associations of patients a pool of skills and interactive exchanges.
Offer channels of learned societies, Associations of patients and the Media of the relays in the communication and promotion of new approaches therapeutic and/or solutions for unmet needs. Offer the contractor a better control of its capital by the various options proposed and enable him to take the capitalistic or strategic orientations by deliberate as long as possible.

Our values

We have a strong commitment to entrepreneurs and rely as much on their teams on their innovative products with high potential.

Human values and in particular the integrity, transparency are at the heart of our concerns. This is not only a financial adventure but above all a human and social adventure.

who speaks

2016

Hoolders, or the era of "co-founding.

Print – January 19, 2016

2015

HOOLDERS and tomorrow's women are mobilizing to promote investment in the feminine

Print – 24 December 2015

Promote investment in the feminine

Print – 23 December 2015

#MaddyMoney: the startup ecosystem has raised EUR 18.5 million this week

Print – 23 October 2015

Health: the power of plants

Print – 23 October 2015

"Neuro-Sys gets €345K for its development"

Print – 22 October 2015

"Co-funding: 345000euros raised by Neuro-Sys"

Print – October 21, 2015

"6 weeks after the opening of subscriptions, Neuro-Sys harvest 345 KE"

Print – October 20, 2015

"Neuro-Sys gets €345K for its development"

Print – October 19, 2015

"Neuro-Sys harvest 345 KE"

Print – October 19, 2015

"Neuro-Sys harvest 345 KE"

Print – October 19, 2015

The "crowdfunding" ready to grow

Print – October 15, 2015

"Fintech: in the shadow of the big banking groups"

Print – 12 October 2015

' Acobiom appealed to the public for 1.5 M€ '

Print – 12 October 2015

"Hoolders, co-funding platform has APPEALED for donations for the COP21"

Print – 4 October 2015

"Volkswagen cheating or l'affaire Kerviel in his time or the Eurotunnel or let's Gowex's are events that will happen again. Unfortunately!"

Print – 4 October 2015

"The biotech fold, but will they break?"

Print – 4 October 2015

"Read, saw, heard, that should not be missed near you."

Print – 3 October 2015

"Angers. They encapsulate drugs"

Press – September 30, 2015

"The Angevin company Carlina Technologies involves participatory funding for his research"

Press – September 30, 2015

"Volatility current accelerated investments in our platform", Harold Zimé, President of Hoolders

Video – September 30, 2015

"Harold Zimé presents the Hoolders company"

Video – September 30, 2015

"We recommend diversification in non-rated groups where access to information is simpler", Harold Zimé, President of Hoolders

Video – September 30, 2015

"Go on the unlisted or cover themselves with and was able to limit the risks", Harold Zimé, President of Hoolders

Video – September 30, 2015

"Hoolders"

Press written – September 28, 2015

"Crowdfunding: what are the promising sectors?"

Press written – September 14, 2015

"Plants are fighting against Alzheimer 's"

Press written – 4 September 2015

' One year after its name change, Acobiom wants to raise 1 M€ '

Press written – 26 August 2015

"Participatory financing: an opportunity for the health sector"

Written press – July 28, 2015

"HOOLDERS, the 1st platform of cofunding"

Written press – July 27, 2015

""Volatility is important but some biotechs have done more than 180% over one year"Thierry de Catheu, specialist biotech"

Video – July 27, 2015

"PARIS / with Hoolders, put your money in the industries and jobs of the future"

Written press – July 24, 2015

'Investing in the capital of undertakings otherwise…'

More and more crowdfunding platforms allow individuals to invest in the capital for SMEs.

Press written – may 2015

"Harold Zime, President and founder of Hoolders" – Silver Economy Expo 2014

Youtube video – January 29, 2015

"Hoolders, invest in the best French start-up, from € 100!"

Webpage – January 29, 2015

"Hoolders"

Web page and Video – 8 January 2015

"Crowdfunding platform Hoolders launches an operation of french motorways redemption"

Print – January 5, 2015

2014

"Hoolders is a platform of financing in equity (equity participation)"

Web page

"Hoolders invites you to the Actionaria"

Web page

"#Startup #Hoolders: a French highway, you are interested?"

Print – December 26, 2014

"#Crowdfunding: Hoolders looks very closely at Wiseed"

Print – December 19, 2014

'Investing alongside finance professionals in French companies'

Print – December 17, 2014

"Hoolders: invest in the best French start-up, from € 100!"

Webpage – 6 December 2014

"HOOLDERS and the Silver Economy Expo launch the 1st live sector crowdfunding"

Print – December 1, 2014

'Noise of corridor user crowdfunding Hoolders platform'

Print – December 2014

"HOOLDERS and Silver Economy Expo launch the 1st live sector crowdfunding"

Print – November 28, 2014

"Hoolders launches the 1st live crowdfunding of the Silver Economy"

Print – November 27, 2014

"Find Hoolders at the Actionaria on November 22"

Web page – November 9, 2014

"Find Hoolders at the Actionaria on November 22"

Web page – November 8, 2014

"Crowdfunding platform Hoolders at the Salon of the Micro Enterprise" print – September 26, 2014

partners

My opinion after the test

Registration

It is not clear except in the TOU to be french or not. L eprocessus is simple

Briefing note

You're almost there! Hoolders will be pleased to assist you in making participation in young companies unlisted. Prior and as a potential investor, please read the following before any approach. At Hoolders, this assistance is free of charge, charges will be levied to cover the operation only at the time of the actual subscription in a company.

Process

The company supports its clients in the financing of their development, through the lifting of funds, the strategic and financial advice. Structureur funding and with the amenities required by the AMF, the company offers various financing options, depending on the legal status of the specifications of its customers (bond, Equity, Credit, good boxes..) in order to achieve the desired funding needs

Selective in its approach – after a phase of screening in internal jury, an intensive due-diligence in 3 steps ended by an external jury (in the Hoolders method annex)-, only 3 to 7% of the received projects are selected. Thus, the selectivity of its process warranty partners historical and investor community, quality records, to strong profitability.

The investment process consists of 8 steps and is described below. Steps 1 to 3 are mandatory when your initial participation.

Inscription on Hoolders.com,
Intelligence of a backgrounder client and advisors of Hoolders SAS analysis to validate the 'Candidates policyholders' risk profile,
Signing of the letter of Hoolders mission in his capacity as Advisor in financial investments,
Discovery of referenced companies and analysis of investment files,.
Reservation of shares as part of the operation,
Launch of the call for funds after the collection of a minimum amount ("feasibility threshold"),
Signature of newsletter subscription and shareholder,
Transfer of funds.

NB: the transfer of funds is required starting from the launch of the official subscription. Subject that society has reached its 'feasibility threshold' and that the operation is confirmed. For reasons of confidentiality, an underwriter applicant may be denied participation in the proposed transaction.

Investment financial advisor

The Hoolders company operates investment financial advisor. Activity regulated and regulated by the financial markets authority and professional associations.

A CIF is a person who carries out the following activities as usual occupation:

the investment advice mentioned in the 5 article L. 321 – 1 of the code monétaire et financier;
the Council on the implementation of investment services referred to in article L. 321 – 1 of the code monétaire et financier;
the Council on the completion of transactions on goods various defined by article L. 541 – 1 of the code monétaire et financier.

Projects

Projects under study are not accessible.

Example of a project

Investing in Innovation for Cancer and Alzheimer's disease while défiscalisant his taxes & plus‐values (I.S.F., PEA, PEA‐PME)
Finance ACOBIOM, is:

Participate in the latest medical INNOVATIONS in Cancer and Alzheimer's disease,
Invest in a growing sector continues (health and medical diagnosis),
Perform a PLUS‐VALUE (an entry on the stock exchange is expected in 2017 if the conditions are met),
DEFISCALISER sound I.S.F. (Tax on wealth) and its plus‐values (PEA, PEA‐PME) by attending the crowdfunding campaign hosted by the HOOLDERS platform (more details on: bit.ly/AcoBiom).

INNOVATION: "give good Patient the right treatment.
Health systems face a significant reduction in their expenses. Meanwhile, the actors of the medical sector are looking for a better efficiency of the prescribed treatments. Thus, according to a U.S. study in 2014 (Personalized Medicine Coalition), 75% of patients suffering from cancers and 70% of patients with Alzheimer's not respond effectively to one drug in particular.
The personalized medicine responds to this double objective of reducing expenditure on health and therapeutic efficiency, because it allows: "give the right treatment to the right Patient.

Indeed, through the use of specific disease diagnostics and biomarkers of efficacy, toxicity, etc., this approach allows to take into account the biological differences of each in order to give the treatment most effective or most suited to the profile of each patient. GROWTH: Medical diagnosis, an indispensable tool and a continuous growth market!
60-70% of medical decisions are based on the results of Diagnostics. These
estimates are confirmed by the growth of this sector. Indeed, the «In Vitro diagnosis» market presents a growth of + 5,34%/an and is expected to reach 75 billion
US$ in 2020. The companion Diagnostic market (diagnosis for predicting the)
good response of a patient to a drug) has meanwhile a growth of
22,69%/an to 8.73 billion US$ in 2019. Sources: Lewing Group, Markets & Markets.
Finance ACOBIOM, but why?
Supported by Bpifrance, ACOBIOM (Montpellier, France) is looking for 0.5 M€ in 2016 for its development of new Diagnostics in personalized medicine, and in particular the last stages of R & D before marketing of new diagnoses in the treatment of cancer (cf pipeline below).
ACOBIOM | 1682, street of the Valsiere ‐ CS77394 ‐ Cap Delta – Biopôle Euromédecine II | 34184 Montpellier Cedex 4 | T: 04 67 41 97 48 | Info@acobiom.com | www.acobiom.com
INNOVATION: ACOBIOM, Diagnostics for "give the right treatment to the right Patient.
GROWTH: ACOBIOM, 1st Diagnostics sales in 2018 and a turnover of €124M in 2022!

PLUS‐value: ACOBIOM, many strengths and prospects plus‐value as early as 2017!

A platform technology owner based on the sequencing and a bio‐informatique dedicated
17 years of expertise, patents and a recognized know‐how (60 scientific publications)
A shareholding consisting of the founders (42%), scientists (3%) and investors (55%): Substipharm, MG Pharma, group Saint Olive, the founders ethypharm (G.Leduc) and Clinisciences (C.Cabau)…

A rigorous financial management:

2.0 M€ obtained equity investors
2.5 M€ obtained in projects of R & D (Europe, Bpifrance, ANR…) & 1.0 M€ of CIR
An important perspective of quick release and plus‐value in the short term for investors:
0.5 M€ to raise capital from investors in 2016
10 M€ at sunrise and one entry planned IPO in 2017 (if the conditions are met)
Stabilized revenues and substantial profitability prospects

Acobiom_actionaria

Why choose ACOBIOM?

For the final stages of R & D before commercialization of diagnostics which have goal to give "the right treatment for the right patient" in the fields of Cancer and Alzheimer's disease

Supported by Bpifrance, Acobiom (Montpellier, France) search 0, 5 M€ from investors to finance its programmes for development and clinical validation of innovative diagnostics related to the treatment of Cancer and Alzheimer's disease, and in particular:

> clinical validation (necessary step…

For the final stages of R & D before commercialization of diagnostics which have goal to give "the right treatment for the right patient" in the fields of Cancer and Alzheimer's disease

> clinical validation (required step before commercialization) of new Diagnostics in cancer of the pancreas (two diagnostic companions and a blood diagnosis of disease),

> the research and development of new Diagnostics in Alzheimer's disease (a companion diagnostic and blood diagnosis of the disease).

The first sales of the diagnosis for cancer of the pancreas are scheduled for 2018. The first sales of diagnostics for Alzheimer's disease are scheduled for 2020.

Acobiom is a total turnover of €142M through its future companions diagnostics and a turnover of 22 M€ through its other diagnoses.

Project

The needs of a better therapeutic efficacy

Faced with the reduction of the overall cost of health systems, as well as to the growing needs of the various players in the sector (patients, physicians, insurance) to improve the effectiveness of the proposed therapies, diagnostics represent an effective solution to help in the choice of treatment. This trend towards a more suited to the "biological profile" medicine the patient is now shared by all stakeholders in health.

Personalized medicine, the medicine of tomorrow

The personalized medicine (or precision medicine) takes into account the biological differences of each in order to administer the treatment most effective or most suited to the biological profile of the patient.

Personalized medicine is thus based on: 1) an accurate diagnosis of diseases; (2) a treatment targeted for each patient; (3) adjusted and scalable dosage during treatment; (4) biomarkers of efficacy, toxicity, of stopping treatment, relapsed…

The sequencing, the most powerful tool to discover biomarkers

Sequencing is recognized today as the tool in molecular biology (Genomics) the most powerful and most efficient to obtain precise information on the information contained in the samples analyzed, in particular on biomarkers involved or associated with certain pathologies or responses of patients to treatments.

The added value of the clinical and financial diagnosis in terms

For many diseases such as cancers, new therapies costs several tens of thousands of euros. Thus, the treatment of cancer of the pancreas by Abraxane (Celgene) would represent an estimated cost of between £ 30,000 and £ 78.500 according the "National Institute for Health and Care Excellence" (Great Britain). However, 75% of the population would fail to a class of drugs in cancer, 70% in Alzheimer's, according to the association 'Personalized Medicine Coalition' (USA).

The companions diagnostics to determine answering patients to certain treatments which are associated with these diagnoses.

The benefits of diagnostics companions are several orders:

> More security of the treatment to which the diagnosis is associated,

> More efficiency of the treatment for the patient,

> Fewer side effects of the treatment for the patient,

> Greater "efficiency" costs for the paying agencies.

Diagnostics companions therefore allow avoiding ineffective treatments and unnecessary expenses, and reorient the patient without delay to other therapeutic alternatives.

According to Markets & Markets, "Diagnosis companion" market is estimated at 3.1 billion dollar in 2014 and $ 8.7 billion in 2019, with an annual growth over 20%.

The discovery of new biomarkers…

Acobiom has developed a technological platform, result of 16 years of developments and expertise, which combines sequencing and bioinformatic programs and Biostatistics owners allowing the processing and analysis of biological and clinical data important (BIG DATA). Acobiom has a recognized expertise (more than 50 scientific publications) in the identification and validation of genomic markers (RNA, Microrna…) of the blood and blood cells.

… to the development of innovative diagnostics

On the basis of biomarker identified in blood by sequencing, Acobiom develops innovative diagnostics for personalized medicine applications: diagnostic companions to distinguish different 'biological profiles' or different subpopulations of patients to predict the effectiveness of a targeted therapy. Acobiom is now involved in the development of several innovative diagnostics: (1) a companion Diagnostic associated with masitinib (molecule of AB Science) in the treatment of cancer of the pancreas, (2) a companion Diagnostic associated with a molecule generic in the treatment of cancer of the pancreas, (3) a companion Diagnostic associated with masitinib in the treatment of Alzheimer's disease…

These diagnoses are real time quantitative PCR technology, technology which allows to validate clinical biomarkers identified by sequencing and which is widely circulated in hospitals across the world.

The project promoters

Services and products

What is (s) product (s) / service (s) proposed (s)?

Acobiom is currently under clinical validation of several diagnosis in the treatment of cancer of the pancreas (338,000 new cases per year worldwide).

Diagnostics companions in cancer of the pancreas are able to predict a higher survival of 12 to 15 months for patients with this pathology.

The first sales expected for 2018 are:

-The companion diagnostic associated with Gemcitabine (generic of the Gemzar), with a turnover expected after 5 years of marketing valued at 17 million € / year;

-Associated with the AB science Masitinib, companion Diagnostics with a turnover expected after 5 years of marketing valued at 32 million € / year;

-The diagnosis of cancer of the pancreas with a turnover expected after 5 years of marketing estimated at 6 million € / year.

For Alzheimer's disease (7.7 million new cases annually worldwide), the first sales expected for 2020 are:

-A companion associated with Masitinib, diagnostic with a turnover expected after 5 years of marketing valued at 93 million € / year;

-A diagnosis of Alzheimer's disease, with a turnover expected after 5 years of marketing valued at 16 million € / year.

PIPELINE: ACOBIOM has other projects concerning cancer of triple-negative breast, prostate and colon cancers, with a maturity of marketing in 2022.

The need

GIVE THE RIGHT TREATMENT TO THE RIGHT PATIENT

Acobiom responds to needs in the field of personalized medicine, by identifying new biomarkers and in developing related diagnoses in order to give the right treatment to the right patient.

These Diagnostics allow to identify and Stratify patients for which a molecule or a therapy will be effective and useful.

Customers

The end user of the companions of Acobiom diagnostics will be hospitals.

Biological analysis from the companion of a new drug diagnosis will be supported in the cost of the new drug. It is the pharmaceutical laboratory that offers the new drug, the partner with whom the couple drug / companion diagnostic has been developed, which will negotiate the price of the medicine and analyses to make. In other words, this pharmaceutical laboratory will offer sponsors of health systems a "package" diagnosis + treatment, which will facilitate refunds and support the diagnosis.

This should be the case with AB Science, which is a privileged partner of Acobiom. This schema should work for the new molecules with high added value in order to justify therapeutic choice and price of new treatments.

For diagnosis companion associated with a generic molecule, such as Gemcitabine, the customer will be the public hospital which will find several interests: limit unnecessary treatments and limit expenses that may be incurred for therapies without benefit.

For Alzheimer's disease, given the support currently highly fragmented patients and the very large number of cases, it will be necessary to establish a distribution partnership with an extensive commercial network player, knowing that the analyses will be performed in a centralized laboratory.

Sales & Marketing strategy

The price analyses (which includes the price of the diagnosis) performed on the basis of diagnostics companions comparable at the technical level to those of Acobiom lies in the range of $ 2,950 (Xdx AlloMap) $ 3,460 (Oncotype Dx Genomic Health). The prices of future companions of Acobiom diagnostics are between 300 euros and 800 euros, depending on the pathology and the price of the medicine to which these tests will be associated.

In the case of cancer of the pancreas, the objective is located between 50% to 60% of patients because it is for the companion of the masitinib diagnosis or to Gemcitabine, these diagnostics will give the right treatment to the right patient, to limit the adverse effects of inadequate treatment and significant savings to health care systems.

Indeed, the cost of treatment with masitinib is today estimated at more than 20,000 euros, that of abraxane to over 40,000 euros in Britain, and that of folfirinox to nearly 12,000 euros, then the gemcitabine has a low cost: less than 1,000 euros. Carry out an analysis which cost between 1,200 euros and 1,500 euros is therefore entirely justifiable economically and medically!

For diagnostics companions associated with new treatments, marketing efforts will be mainly conducted by the pharmaceutical partner because the authorisation for the placing on the market of the molecule will be most likely given honours diagnosis 'required' or 'recommended '.

With regard to diagnostics companions associated molecules already on the market, such as gemcitabine, marketing efforts will be at several levels: scientific publication, presentation of the results in scientific seminars, and canvassing. For cancer of the pancreas, about 400 hospitals deal with this disease in Europe and North America.

Business Model

The Business model of Acobiom is mixed:

> sales of services to identify or validate biomarkers

> sale of diagnostics and diagnostics companions.

By 2015, Acobiom does not yet generate revenue on its pole diagnosis and not enough on his pole services to self-finance its R & D.

This need for funding should continue in 2016 and 2017 for the clinical studies of society, whose costs are important (€3000 to 5000 per patient). This is the reason why Acobiom is looking for investors and new funding.

The advantages of products

The biomarkers identified by Acobiom are specific of the molecule to which they are associated. In addition, developed diagnostics provide a sensitivity and reproducibility important, not to mention the fact that they are associated with a good response to treatment.

Thus, diagnostic companions associated treatments in cancer of the pancreas can predict a favorable response to a category/subpopulation of patients, and improve the median survival of patients.

The key for success

Today, Acobiom seeks to validate the relevance of its companions diagnostics on a large population and demonstrate as well as its diagnostics can effectively predict the good response of the patient to the proposed treatment (which is associated with the companion diagnostic).

The recruitment of sufficient number of patients during the phases of clinical trials is important to validate both the new treatment and the quality of the companion diagnostic.

Barriers to entry to the market

Acobiom filed three international patents that protect its companions diagnostics in cancer of the pancreas.

It will be very difficult for a potential competitor to return to any work, including redo a clinical study to propose a new test companion, whether it be the masitinib for gemcitabine.

Indeed, should that competing diagnostics reflect none of the components of the companions of Acobiom diagnostics in cancer of the pancreas and demonstrate at the same time superior to the diagnostics of Acobiom efficiency. The cost and risk are extremely important and do not justify the necessary investments on the part of a competitor.

In addition, in therapies against cancer (for example) for which a high percentage of patients do not respond to a given molecule, authorisations for the placing on the market will be more and more conditioned by the performance with the molecule / companion diagnostic.

Launch date and number of customers

ACOBIOM has been created on 1999-07-01: There are to date 50 customers

What is the price of sale of the products/services you sell?

Future diagnostics companions of Acobiom prices will range between 300 and 800 euros, depending on the pathology and the price of the medicine to which these diagnoses will be associated.

The price analyses (which includes the price of the diagnosis) performed on the basis of diagnostics companions comparable at the technical level to those of Acobiom lies in a range between $ 2,950 (Xdx AlloMap) and $ 3,460 (Oncotype Dx Genomic Health).

Main charge fixed or variable

Payroll is the main fixed charge. R & D and product development are largely outsourced.

Average customer acquisition cost

1000

The business is already profitable

Non

Competition

Name/Type	Roche Diagnostics
Service/product description	Roche Diagnostics offers equipment certified by the US agency FDA for analysis of biomarkers and diagnostics companions for some cancers, including breast cancer.
The forces of the competitor	Roche Diagnostics is a major player in the diagnosis in vitro and molecular biology with a force and a significant commercial presence.
Its weaknesses	The R & D of Roche Diagnostics is very focused on hardware (which generates the most revenue), less on biomarkers. This subject, this company has repurchased companies who owned diagnostics companions of some cancers. Roche Diagnostics offers diagnoses of cancers on itself, not on tissues in the blood, easier to collect and analyze.
Its turnover	10800
Beneficiary	Novartis.
Distribution network	World
Business strategy	First sell the devices / platforms, then propose the consumables / diagnostics in vitro, including in "personalized" treatments
Elements of differentiation	Roche Diagnostics focuses on important markets/pathologies, while Acobiom has rather a niche positioning, with the exception of Alzheimer's disease for which there is no diagnosis and diagnostic reliable companion.
Market share	10
Capital	15965175

ACOBIOM

Sector: health

€ 500,000 to collect

There are 32% of the total amount which is funded with:

–€10,000 of the total amount is funded.

-€153 700 in progress.

Montpellier Cedex 4

2 recommendations

56 followers

https://hoolders.com/share/LinkedIn/212/

my opinion

We speak actually start up and too d taxes or more value in the prospectus, however in the topic we are clearly saying that the company is not profitable at the end of 17 years. (notice the relevance of this question which is on hoolders, it is a good point). Personally, it is not a project in which I will put money.

hoolders investment crowdfunding innovation co-investment 34 carriers project

The figures are everywhere which is a bit of a hassle, in the prospectus it y the financing plan (very good point).

Capital, its amount and the actionnaires(enfin si, qui détient combien de pourcentages, mais pas combien cela représente), j not found (may be my fault, there is no doubt) damage, all is not necessarily a priority if it is bond, as this is more important if shareholder.

Need to register at the hoolders club?

Welcome to the Hoolders Club!

Hoolders is the 1st French co-funding PREMIUM platform, dedicated to innovative companies of the silver economy, health and connected objects.

In order to give you access to a premium service and your enjoyable investment, today we launch the Hoolders Club.

This club closed, whose recruitment is carried out by co-optation (ed. by piston /connaissance network /parrainage therefore), gives you access to several benefits including:

With 1 click, companies that you believe will be co-funder to 2 000 investors.
Free investment costs *.
Privileged access to the network of sectoral experts

As additional benefits, you'll have access:

the network of industry experts
the profile of the other members of the club. With the possibility of exchanges of good practices, notice of concerns:
- Pooling of investment risks
- Taxation of your heritage
- Exchange on the arguments of investment decision
- Find opportunities for consulting / customers / meetings.
aid on the valuation of a company
the strategic Committee of each of the companies where you have invested to represent the interest of the crowd

hoolders investment crowdfunding innovation co-investment 16 club

(*) As a member of the club, the investment expenses you are offered up to 20,000 euros invested per calendar year.

https://hoolders.com/register/hooldersclub/

Yes clearly it is necessary to register at the hoolders club, because without the costs, profitability is completely different and much better. But this also makes hoolders a crowdfunding site at two speeds. Each will be able to take full advantage of the site and others will be more limited, indeed it should be remembered that hoolders for the initial commission costs corresponds to 5% of the amount of the investment proposed by the investor, duty-free.

Off 5% more or less makes a huge difference in my experience. It's a very good life insurance performance!

example: invest € 1000, with costs the other without. interest paid 1 time per year

1000 * 0, 95% = €950

Suppose that the two sites have 5% annual return.

with costs at the end of 5 years € 1212

toll-free qu end 5-year 1276

difference €64

with costs 10 years € 1547

toll-free 10 value of capital € 1628

difference €81
with profitability of 10%

with costs at the end of 5 years € 1529

toll-free qu bout 5 years € 1610

difference €81

with costs 10 years € 2464

free of charge 10 € 2593

difference: €129
with profitability of 2%
with costs at the end of 5 years € 1048

free of charge after 5 years € 1104

difference €56

with costs 10 years € 1158

free of charge 10 € 1218

difference €60

The difference is important in the case of low yields (performance becomes bad because fees are not well absorbed by the low yield) or in high yields because of the play of interests composed.

Bug and negative points

A page bug completely to 26/03/2016

I do not like the presentation at the level of the shares in the prospectus

The fact that the company is not profitable and it boast a + tax exemption. The tax exemption is the icing on the cake, not the cake. At the same time the research and development have not been known to be profitable immediately

Mixed

The club

The positive points of the platform.

The idea

The fact that the hoolders shareholders are also investing.

the concept is really very interesting

The relevant question on the projects.

Conclusion and my opinion

Interesting concept, it is possible to invest there easily. The ticket input is just average, and projects are more plans for the future that of profitability. However they may honestly be in a good portfolio.

What is Hoolders? The description of the company.

HOOLDERS is the 1st platform of CO-FUNDING in France.

Investors

Why invest in hoolders?

To grow its savings and earn money

Because the principle is really different

Because the interests of hoolders are yours

To diversify your savings

Because you decide

Because the ticket is affordable

To diversify

To have a tax deduction

Hoolders, frequently asked questions

Who can invest?

What are the costs?

How to invest?

How much invest and what benefits?

RIGHT OF WITHDRAWAL (BLOGS L.343‐1 AND FOLLOWING OF THE CODE OF MONETARY AND FINANCIAL)

What is the risk?

Taxation

Entrepreneurs

Why trust hoolders?

Frequently asked questions

What are the selection criteria?

how much can I borrow?

How to create my project on Hoolders?

I am entrepreneur, how to protect confidential information in my project?

I am a company or an association, I would like to work towards more ethical and solidarity

Where to find further information?

What is your process?

WHERE to place a folder?

How to succeed its fundraising?

How can I convince investors?

Who should I contact?

How is fundraising for Hoolders

Other information

Sponsorship

Who is hoolders?

Team

the team leader

the strategic Committee

The selection board

HOOLDERS health

who speaks

partners

My opinion after the test

Registration

It is not clear except in the TOU to be french or not. L eprocessus is simple

Menu

Projects

Example of a project

Philippe Outrebon

Ritter Didier

my opinion

Need to register at the hoolders club?

Bug and negative points

A page bug completely to 26/03/2016

Mixed

The positive points of the platform.

Conclusion and my opinion

Partager :

Laisser un commentaire Annuler la réponse

Veux-tu commencer à construire ton patrimoine ?

Recevez nos petits secrets pour devenir riche.